Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment(1)

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7875-7882

  Reich, Reuven ^a   Hoffman, Amnon ^a   Veerendhar, Ainelly ^a   Maresca, Alfonso ^b   Innocenti, Alessio ^b   Supuran, Claudiu T ^b   Breuer, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIN 19; BIN 3; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; JS 268; JS 294; JS 325; JS 343; JS 389; JS 403; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; YK 102; YK 103; YK 111; YK 137; YK 145; YK 146; YK 83; YK 9; YK 96;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CELL HYPOXIA; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; IC 50; PROTEIN DOMAIN; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CELL LINE, TUMOR; HUMANS; MATRIX METALLOPROTEINASE 2; ORGANOPHOSPHONATES; PROTEASE INHIBITORS; TUMOR MICROENVIRONMENT;

EID: 84866307412     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300981b     Document Type: Article

References (66)

1. Li, N. G.; Shi, Z.-H.; Tang, Y. P.; Duan, J. A. Selective matrix metalloproteinase inhibitors for cancer Curr. Med. Chem. 2009, 16, 3805-3827
2. Bourguet, E.; Sapi, J.; Emonard, H.; Hornebeck, W. Control of melanoma invasiveness by anticollagenolytic agents: A reappraisal of an old concept Anti-Cancer Ag. Med. Chem. 2009, 9, 576-597
3. Friedl, P.; Wolf, K.; Travel, T. The role of proteases in individual and collective cancer cell invasion Cancer Res. 2008, 68, 7247-7249
4. Hu, J.; Van den Steen, P. E.; Sang, Q.-X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases Nat. Rev. Drug Discovery 2007, 6, 480-498 (Pubitemid 47064570)
5. Ahrens, D.; Koch, A. E.; Pope, R. M.; Steinpicarella, M.; Niedbala, M. J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis Arthritis Rheumatism 1996, 39, 1576
6. Blaser, J.; Triebel, S.; Maasjosthusmann, U.; Romisch, J.; Krahlmateblowski, U.; Freudenberg, W.; Fricke, R.; Tschesche, H. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis Clin. Chim. Acta 1996, 244, 17-33 (Pubitemid 26053175)
7. Bottomley, K. M.; Johnson, W. H.; Walter, D. S. Matrix metalloproteinase inhibitors in arthritis J. Enzyme Inhibit. 1998, 13, 79-101 (Pubitemid 28230676)
8. Tezuka, K.; Nemato, K.; Tezuka, Y.; Sato, T.; Ikeda, Y.; Kobori, M.; Kawashima, H.; Eguchi, H.; Hakeda, Y.; Kumegawa, M. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts J. Biol. Chem. 1994, 269, 1106
9. Ohishi, K.; Fujita, N.; Morinaga, Y.; Tsuruo, T. H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption Clin. Exp. Metastasis 1995, 13, 287-295
10. Witty, J. P.; Foster, S. A.; Stricklin, G. P.; Matrisian, L. M.; Stern, P. H. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B J. Bone Mineral Res. 1996, 11, 72-78 (Pubitemid 26026746)
11. Woessner, J. F., Jr. The family of matrix metalloproteinases Ann. N. Y. Acad. Sci. 1994, 732, 11-21
12. Celentano, D. C.; Frishman, W. H. Matrix metalloproteinases and coronary artery disease: a novel therapeutic target J. Clin. Pharmacol. 1997, 37, 991-1000 (Pubitemid 27524557)
13. Lorenzl, P. R.; Koedel, S.; Sporer, U.; Vogel, B.; Frosch, U.; Pfister, M. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis Ann. Neurol. 1998, 44, 592-600
14. White, A. D.; Bocan, T. M.A.; Boxer, P, A.; Peterson, J. T.; Schrier, D., Emerging therapeutic advances for the generation matrix metalloproteinase inhibitors Curr. Pharm. Design 1997, 3, 45-58 (Pubitemid 27215887)
15. Armstrong, P. W.; Moe, G. W.; Howard, R. J.; Grima, E. A.; Cruz, T. F. Structural remodelling in heart failure: gelatinase induction Can. J. Cardiol. 1994, 10, 214
16. Suzuki, R.; Miyazaki, Y.; Takagi, K.; Torii, K.; Taniguchi, H. Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy Treat. Respir. Med. 2004, 3, 17-27 (Pubitemid 38444328)
17. Fukuda, E. M.; Nakano, Y.; Katano, I.; Fujimoto, Y.; Hayakawa, N. Serum levels of TIMP-2 and MMP-2 in patients with liver disease Liver 1997, 17, 293-299
18. Romanic, A. M.; White, R. F.; Arleth, A. J.; Ohlstein, E. H.; Barone, F. C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size Stroke 1998, 29, 1020-1030 (Pubitemid 28228167)
19. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papatsoris, A. G.; Papavassiliou, A. G. Matrix metalloproteinase inhibitors as anticancer agents Int. J. Biochem. Cell Biol. 2008, 40, 1156-1168
20. Sang, Q.-X. A.; Jin, Y.; Newcomer, R. G.; Monroe, S. C.; Fang, X.; Hurst, D. R.; Lee, S.; Cao, Q.; Schwartz, M. A. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases Curr. Topics Med. Chem 2006, 6, 289-316
21. Krüger, A.; Kates, R. E.; Edwards, D. R. Avoiding spam in the proteolytic internet: Future strategies for anti-metastatic MMP inhibition Biochim. Biophys. Acta 2010, 1803, 95-102
22. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for the highly selective inhibition of MMP-13 Chem. Biol. 2005, 12, 181-189 (Pubitemid 40281325)
23. Pochetti, G.; Montanari, R.; Gege, C.; Chevrier, C.; Taveras, A. G.; Mazza, F. Extra binding region induced by non-zinc chelating inhibitors into the S1′ subsite of matrix metalloproteinase 8 (MMP-8) J. Med. Chem. 2009, 52, 1040-1049
24. Devel, L.; Rogakos, V.; David, A.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of selective inhibitors and substrate of matrix metalloproteinase-12 J. Biol. Chem. 2006, 281, 11152-11160 (Pubitemid 43855540)
25. Veerendhar, A.; Reich, R.; Breuer, E. Phosphorus based inhibitors of matrix metalloproteinases C. R. Chimie 2010, 13, 1191-1202
26. López-Otín, C.; Matrisian, L. M. Emerging roles of proteases in tumour suppression Nat. Rev. Cancer 2007, 7, 800-808 (Pubitemid 47463671)
27. Morrison, C. J.; Butler, G. S.; Rodriguez, D.; Overall, C. M. Matrix metalloproteinase proteomics: substrates, targets, and therapy Curr. Opin. Cell Biol. 2009, 21, 645-653
28. Farkas, E.; Katz, Y.; Bhusare, S.; Reich, R.; Röschenthaler, G.-V.; Königsmann, M.; Breuer, E. Carbamoylphosphonate Based Matrix Metalloproteinase (MMP) Inhibitor Metal Complexes-Solution Studies and Stability Constants. Towards a Zinc Selective Binding Group J. Biol. Inorg. Chem. 2004, 9, 307-315 (Pubitemid 38595915)
29. Breuer, E.; Salomon, C. J.; Katz, Y.; Chen, W.; Lu, S.; Röschenthaler, G.-V.; Hadar, R.; Reich, R. Carbamoylphosphonates-A New Class of In Vivo Active Matrix Metalloproteinase Inhibitors 1. Alkyl- and Cycloalkylcarbamoylphosphonic acids J. Med. Chem. 2004, 47, 2826-2832 (Pubitemid 38656735)
30. Reich, R.; Katz, Y.; Hadar, R.; Breuer, E. Carbamoylphosphonate MMP inhibitors 3. In vivo evaluation of cyclopentylcarbamoylphosphonic acid, CPCPA, in experimental metastasis and angiogenesis Clin. Cancer Res. 2005, 11, 3925-3929 (Pubitemid 40685614)
31. Breuer, E.; Katz, Y.; Hadar, R.; Reich, R. Carbamoylphosphonate MMP Inhibitors 4. The influence of chirality and geometrical isomerism on the potency and selectivity of inhibition Tetrahedron: Asymmetry 2004, 15, 2415-2420 (Pubitemid 39092300)
32. Hoffman, A.; Qadri, B.; Frant, J.; Katz, Y.; Bhusare, S.; Breuer, E.; Hadar, R.; Reich, R. Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 6. cis -2-Aminocyclohexylcarbamoyl phosphonic Acid. A Novel Orally Active Antimetastatic Matrix Metalloproteinase-2 Selective Inhibitor -Synthesis, and Pharmacodynamic and Pharmacokinetic Analysis J. Med. Chem. 2008, 51, 1406-1414 (Pubitemid 351480402)
33. Frant, J.; Veerendhar, A.; Chernilovsky, T.; Nedvetzki, S.; Vaksman, O.; Hoffman, A.; Breuer, E.; Reich, R. Carbamoylphosphonates 9-Orally active, antimetastatic, non-toxic, diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors ChemMedChem 2011, 6, 1471-1477
34. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators Nat. Rev. Drug Discovery 2008, 7, 168-181 (Pubitemid 351194064)
35. Supuran, C. T. Carbonic anhydrases as drug targets - general presentation. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C. T.; Winum, J.-Y., Eds.; Wiley: Hoboken, 2009; pp 15-38.
36. Winum, J.-Y.; Montero, J.-L.; Scozzafava, A.; Supuran, C. T. Zinc binding functions in the design of carbonic anhydrase inhibitors. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C. T.; Winum, J.-Y., Eds.; Wiley: Hoboken, 2009; pp 39-72.
37. Alterio, V.; Di Fiore, A.; D'Ambrosio, K.; Supuran, C. T.; De Simone, G. X-Ray crystallography of CA inhibitors and its importance in drug design. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C. T.; Winum, J.-Y., Eds.; Wiley: Hoboken, 2009; pp 73-138.
38. Alterio, V.; Di Fiore, A.; D'Ambrosio, K.; Supuran, C. T.; De Simone, G. Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms? Chem. Rev. 2012, 112, 4421-4468
39. Svastová, E.; Hulíková, A.; Rafajová, M.; Zat'ovicová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastoreková, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH FEBS Lett. 2004, 577, 439-445 (Pubitemid 39535327)
40. Neri, D.; Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discovery 2011, 10, 767-777
41. McDonald, P. C.; Winum, J.-Y.; Supuran, C. T.; Dedhar, S. Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics Oncotarget 2012, 3, 84-97
42. Lou, Y.; McDonald, P. C.; Oloumi, A.; Chia, S. K.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D. G.; Clarke, B.; Sutherland, B. W.; Waterhouse, D.; Bally, M. B.; Roskelley, C. D.; Overall, C. M.; Minchinton, A.; Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J. Y.; Supuran, C. T.; Dedhar, S. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors Cancer Res. 2011, 71, 3364-76
43. McIntyre, A.; Patiar, S.; Wigfield, S.; Li, J. L.; Ledaki, I.; Turley, H.; Leek, R.; Snell, C.; Gatter, K.; Sly, W. S.; Vaughan-Jones, R. D.; Swietach, P.; Harris, A. L. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy Clin. Cancer Res. 2012, 18, 3100-11
44. Chen, R.; Schlossman, A.; Breuer, E.; Hägele, G.; Tillmann, C.; Van Gelder, J. M.; Golomb, G. Long-Chain Functional Bisphosphonates: Synthesis, Anticalcification, and Antiresorption Activity Heteroatom Chem. 2000, 11, 470-479 (Pubitemid 32074837)
45. Harel, E.; Rubinstein, A.; Chen, W.; Breuer, E.; Tirosh, B. Aminoalkylcarbamoylphosphonates reduce TNFa release from activated immune cells Bioorg. Med. Chem. Lett. 2010, 20, 6518-6523
46. Frant, J. Ph.D. Thesis; Hebrew University of Jerusalem, 2010.
47. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastoreková, S.; Scozzafava, A.; Winum, J. Y.; Montero, J. L.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors J. Med. Chem. 2005, 48, 4834-4841 (Pubitemid 41033126)
48. Pastorekova, S.; Pastorek, J. in Carbonic Anhydrase-Its Inhibitors and Activators, Supuran, C. T., Ed.; CRC Press: Boca Raton, 2004; pp 255-281.
49. Reich, R.; Blumenthal, M.; Liscovitch, M. Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells Clin. Exp. Metastasis 1995, 13, 134-140
50. Grant, D. S.; Tashiro, K.; Segui-Real, B.; Yamada, Y.; Martin, G. R.; Kleinman, H. K. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro Cell 1989, 58, 933-943 (Pubitemid 19227901)
51. Stockwin, L. H.; Blonder, J.; Bumke, M. A.; Lucas, D. A.; Chan, K. C.; Conrads, T. P.; Issaq, H. J.; Veenstra, T. D.; Newton, D. L.; Rybak, S. M. Proteomic Analysis of Plasma Membrane from Hypoxia-Adapted Malignant Melanoma J. Proteome Res. 2006, 5, 2996-3007 (Pubitemid 44749218)
52. Rusconi, S.; Innocenti, A.; Vullo, D.; Mastrolorenzo, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet Bioorg. Med. Chem. Lett. 2004, 14, 5763-5767 (Pubitemid 39421516)
53. Winum, J.-Y.; Innocenti, A.; Gagnard, V.; Montero, J.-L.; Scozzafava, A.; Vullo, D.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates Bioorg. Med. Chem. Lett. 2005, 15, 1683-1686 (Pubitemid 40312552)
54. Temperini, C.; Innocenti, A.; Guerri, A.; Scozzafava, A.; Rusconi, S.; Supuran, C. T. Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase Bioorg. Med. Chem. Lett. 2007, 17, 2210-2215 (Pubitemid 46501767)
55. De Simone, G.; Supuran, C. T. (In)organic anions as carbonic anhydrase inhibitors J. Inorg. Biochem. 2012, 111, 117-129
56. Scozzafava, A.; Supuran, C. T. Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N -Hydroxysulfonamides Inhibit Both These Zinc Enzymes J. Med. Chem. 2000, 43, 3677-3687
57. Esteves, M. A.; Ortet, O.; Capelo, A.; Supuran, C. T.; Marques, S. M.; Santos, M. A. New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 3623-3627
58. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats Arthritis Rheum. 2003, 48, 1742-1749 (Pubitemid 36682383)
59. O'Brien, E. C.; Farkas, E.; Gil, M. J.; Fitzgerald, D.; Castineras, A.; Nolan, K. B. Metal complexes of salicylhydroxamic acid (H(2)Sha), anthranilic hydroxamic acid and benzohydroxamic acid. Crystal and molecular structure of [Cu(phen)(2)(Cl)] Cl center dot H(2)Sha, a model for a peroxidase-inhibitor complex J. Inorg. Biochem. 2000, 79, 47-51 (Pubitemid 30628711)
60. Breuer, E.; Frant, J.; Reich, R. Recent Non Hydroxamate Matrix Metalloproteinase Inhibitors Expert Opin. Ther. Patents 2005, 15, 253-269 (Pubitemid 40403380)
61. Goodsell, D. S. Biomolecules and Nanotechnology American Scientist 2000, 88, 230
62. Ohlson, S. Designing transient binding drugs: A new concept for drug discovery Drug Discovery Today 2008, 13, 433-439
63. It has been pointed out by the authors of the following paper that vorinostat was better than its numerous higher potency analogs, which had unacceptable side effects and, therefore, had to be discontinued: Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25, 84-90 (Pubitemid 46087907)
64. Jahnke, W.; Henry, C. An in vitro assay to measure targeted drug delivery to bone mineral ChemMedChem 2010, 5, 770-776
65. Maresca, A.; Temperini, C.; Vu, H.; Pham, N. B.; Poulsen, S.-A..; Scozzafava, A.; Quinn, R. J.; Supuran, C. T. Non-Zinc Mediated Inhibition of Carbonic Anhydrases: Coumarins Are a New Class of Suicide Inhibitors J. Am. Chem. Soc. 2009, 131, 3057-3062
66. Tabakman, R.; Lazarovici, P.; Kohen, R. Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia J. Neurosci. Res. 2002, 68, 463-469 (Pubitemid 34461577)